![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Broadcom
AVGO
Micron Technology
MU
Alibaba
BABA
NVIDIA
NVDA
Taiwan Semiconductor
TSM
US Stock MarketDetailed Quotes
CRBU Caribou Biosciences
- 1.200
- -0.040-3.23%
Close Feb 26 16:00 ET
108.66MMarket Cap-0.72P/E (TTM)
1.250High1.175Low1.73MVolume1.250Open1.240Pre Close2.09MTurnover2.12%Turnover RatioLossP/E (Static)90.55MShares7.93052wk High0.39P/B97.84MFloat Cap1.17552wk Low--Dividend TTM81.54MShs Float32.645Historical High--Div YieldTTM6.09%Amplitude1.175Historical Low1.211Avg Price1Lot Size
Caribou Biosciences Stock Forum
Sign in to post a comment
$Caribou Biosciences (CRBU.US)$ Next one to fly 👀.
11
$Caribou Biosciences (CRBU.US)$
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
$Caribou Biosciences (CRBU.US)$
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
3
15
$Caribou Biosciences (CRBU.US)$ Reuters· just
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
2
$Caribou Biosciences (CRBU.US)$
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
1
$Caribou Biosciences (CRBU.US)$ Got a inverted hammer on the daily! Its wick actually broke above the downtrend continuation wedge! Its Really OS RSI 7 = 14.58! RSI 14 = 24.96! MACD Looks as if its fixing to GC? So lets just see how this turns out? Just thinking outloud![]()
3
3
$Caribou Biosciences (CRBU.US)$ Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
2
Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
HOHA888 : Hi what do you think is a good TP target? My average is around $1.50
FattyChick OP HOHA888 : >1.70
HOHA888 FattyChick OP : okay thanks!
FattyChick OP HOHA888 : Long term >$6
HOHA888 FattyChick OP : Long term as in? Abt half a year?
View more comments...